Patient P-01595

Synthetic patientNBL-101 · Day 103 · 55–64 · M · baseline S14Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Improving

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Improving

Discontinuation risk

69%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 50 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 50 GI-04 recommended — GI Support Protocol GI-04
Day 51 Patient accepted — Started GI-04 in the companion
Day 59 No meaningful change — GI Support Protocol GI-04
Day 59 ME-01 recommended — Monitoring Escalation ME-01
Day 60 Patient accepted — Started ME-01 in the companion
Day 63 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 50.

Primary contributors, last 14 days

Inflammatory activity-10
Nutritional resilience+9
Treatment adherence+8
GI instability-7
Toxicity-7

What helped?

GI Support Protocol GI-04Day 50
Result: no meaningful change
Monitoring Escalation ME-01Day 59
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dietary Support Protocol NP-02

54%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

57/100

improving · -2.9 vs previous 14 d

Toxicity

Blood

48/100

improving · -6.2 vs previous 14 d

Sleep quality

Wearable

17.1/100

improving · +0.6 vs previous 14 d

Energy level

Daily log

3.1/10

improving · +0.1 vs previous 14 d

Stress level

Daily log

6.6/10

improving · -0.5 vs previous 14 d

Steps

Wearable

5,170

stable · -61 vs previous 14 d

Adherence

Companion

52.7 %

worsening · -4.1 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards restoration · 34 from the failing basin, 56 from restoration.

Would help

NP-02 Dietary Support Protocol
63% improved among 64 similar · onset 10 d · confidence 64%
SC-12 Supportive Compound
76% improved among 51 similar · onset 6 d · confidence 64%
CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 64%

Would not help

GI-04 GI Support Protocol
already tried, no meaningful change
Keep fat low
GI +4.4 next day on high-intake days · n 28
Keep histamine low
GI +4 next day on high-intake days · n 22
Keep simple carbs low
GI +3.3 next day on high-intake days · n 20

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+4.4detractor · 95%
Histamine load
+4detractor · 95%
Simple carbohydrates
+3.3detractor · 95%
Spicy / capsaicin
+3.2detractor · 95%
Alcohol
+3detractor · 95%
Insoluble fibre
+0.3no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 57 and rising
- WearableSleep 5.1 h, below personal baseline
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 31/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 51
- WearableHRV 33 ms, trending down
Drug metabolism and exposure ↑20
- BloodToxicity index 48
Autonomic recovery ↑20
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Intermediate metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.1 · butyrate capacity 31/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 32 ms
Sleep: 5.2 h
Steps: 4,682
Resting HR: 74 bpm

Daily log: GI score 57, nutritional resilience 42, adherence 53.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01782	60%	S14	NP-02	no change	48
P-01311	56%	S14	ME-01	improved	49
P-01465	55%	S14	NP-02	improved	56
P-01751	55%	S14	ME-01	improved	48
P-01732	54%	S14	ME-01	improved	45
P-01834	54%	S14	NP-02	improved	44
P-01482	52%	S14	GI-04	improved	47
P-01843	52%	S14	SC-12	no change	45
P-01872	52%	S14	NP-02	improved	47
P-01576	51%	S14	NP-02	no change	49
P-01409	50%	S14	SC-12	improved	41
P-01573	50%	S14	GI-04	improved	49